PMV Pharmaceuticals
PMVP
70 hedge funds and large institutions have $58.8M invested in PMV Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 31 reducing their positions, and 10 closing their positions.
505% more call options, than puts
Call options by funds: $115K | Put options by funds: $19K
1% more capital invested
Capital invested by funds: $58.2M → $58.8M (+$680K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.46% less ownership
Funds ownership: 75.75% → 75.28% (-0.46%)
5% less funds holding
Funds holding: 74 → 70 (-4)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
52% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.82M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$849K |
| 3 |
SCM
Sio Capital Management
New York
|
+$567K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$153K |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.5M |
| 2 |
PCS
Personal CFO Solutions
Chester,
New Jersey
|
-$820K |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
-$657K |
| 4 |
Goldman Sachs
New York
|
-$616K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$317K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$39.1K | -26,257 | Closed |
|
77
Amundi
Paris,
France
| – | -$38.9K | -26,182 | Closed |
|
|
HP
78
Harbourvest Partners
Boston,
Massachusetts
| – | -$17.2K | -11,533 | Closed |
|
|
CFM
79
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$3.13K | -2,100 | Closed |
|
|
NA
80
Nordwand Advisors
Radnor,
Pennsylvania
| – | -$2.98K | -2,000 | Closed |
|
PMVP Hedge Fund Activity: Q4 2024 in Review
70 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2024, worth a combined $58.8M — up 1.2% from $58.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PMVP and 6 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 15 added.
The largest buyer was BML Capital Management, adding an estimated $2.82M. The largest seller was Citadel Advisors, cutting an estimated $1.5M.
- 70 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2024, down from 74 in Q3 2024.
- Funds reported $58.8M of PMV Pharmaceuticals stock for Q4 2024, up 1.2% quarter-over-quarter.
- 6 funds opened new PMV Pharmaceuticals positions in Q4 2024 and 10 closed out, a net change of -4 holders.
- The largest PMV Pharmaceuticals buyer in Q4 2024 was BML Capital Management, an estimated $2.82M added.
- The largest PMV Pharmaceuticals seller in Q4 2024 was Citadel Advisors, an estimated $1.5M sold.
Based on aggregated 13F filings for Q4 2024.